Ann: Invion - successful completion of P2 study of INV102, page-12

First 12 Last

Share
Profile

Follow
absolutely clueless

1,206 Posts.

116

05/10/15

13:23

Post #: 16115476
Share

Originally posted by w27 ↑

Anyone who does not believe in this company now should not be investing in biotechs. With the deal with Hovione, the Zafirulkast programme is totally de-risked. The drug has been proven safe and effective in previous trials. It was only awaiting a suitable formulation when the previous propellant (cfc) was banned. Hovione will provide that. The latest results for Cpn10, along with extensive results from previous trials, notwithstanding the very poor design of those trials, are at least sufficient for the major cost of further development being accepted by other drug companies. The latest trial results completely underwrite the hypothesis Invion (and their academic collaborators) have proposed around Nadolol. It is all speed ahead for an oral smoking cessation drug. Given the legal problems Pfizer is having with their "standard of care" drug at the moment, I would say that they cannot let this pass into the hands of any other party. The inhaled programme is totally underwritten. Any reasonable valuation would come in above $2.

Expand

I don't know how long the market will continue to value this company at 12 million.
The smoking cessation results alone are in the ball park with Pfizer and Glaxo.... without the suicidal thoughts. We just need a deal NOT more dilution.

IVX Price at posting: 1.4¢ Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

NEU

Neuren jumps over +11% on patent win for Pitt Hopkins drug treatment

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

NMT

Neometals-MinRes JV inks MOU with Rio Tinto on lithium electrolysis

PAR

Paradigm adds new oral combo IP to osteoarthritis drug stable with $500K pick-up

First 12 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 11.0¢		Change 0.000(0.00%)		Mkt cap ! $9.336M

Open	High	Low	Value	Volume
11.5¢	11.5¢	11.0¢	$2	21

Buyers (Bids)

No.	Vol.	Price($)
2	30000	10.0¢

Sellers (Offers)

Price($)	Vol.	No.
11.0¢	45833	3

View Market Depth

No.	Vol.	Price($)
2	30000	0.100
1	20000	0.080
1	50000	0.065
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.110	45833	3
0.115	5667	2
0.120	4415	1
0.125	36518	2
0.135	17000	1

Last trade - 12.28pm 26/06/2025 (20 minute delay)

IVX (ASX) Chart

Ann: Invion - successful completion of P2 study of INV102, page-12

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Neuren jumps over +11% on patent win for Pitt Hopkins drug treatment

Australia’s gas crisis is here – and dying coal plants aren’t helping

Neometals-MinRes JV inks MOU with Rio Tinto on lithium electrolysis

Paradigm adds new oral combo IP to osteoarthritis drug stable with $500K pick-up

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Invion - successful completion of P2 study of INV102, page-12

Top Stories

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Neuren jumps over +11% on patent win for Pitt Hopkins drug treatment

Australia’s gas crisis is here – and dying coal plants aren’t helping

Neometals-MinRes JV inks MOU with Rio Tinto on lithium electrolysis

Paradigm adds new oral combo IP to osteoarthritis drug stable with $500K pick-up

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News